Jun Luo

Citace

	Všechny	Od 2020
Citace	21339	9252
h-index	67	48
i10-index	130	111

2200

1100

550

1650

20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202593 150 242 250 263 265 275 298 419 442 505 744 778 1015 1468 1416 1478 1729 1867 2139 1831 1606 1516 284

Veřejný přístup

Zobrazit všechny

100 článků

5 článků

dostupné

nedostupné

Vychází ze zplnomocnění pro financování

Spoluautoři

William B. IsaacsProfessor of Urology and Oncology, Brady Urological Inst, Johns Hopkins Univ, School of MedicineE-mailová adresa ověřena na: jhmi.edu
Emmanuel S. Antonarakis, M.D.Clark Endowed Professor of Medicine, University of MinnesotaE-mailová adresa ověřena na: umn.edu
Angelo M. De Marzo M.D., Ph.D.Professor of Pathology, Urology and Oncology, The Johns Hopkins University School of MedicineE-mailová adresa ověřena na: jhmi.edu
samuel denmeadeE-mailová adresa ověřena na: jhmi.edu
Mario EisenbergerProfessor of Oncology,Johns Hopkins UniversityE-mailová adresa ověřena na: jhmi.edu
Mari Nakazawa, M.D.Johns Hopkins School of MedicineE-mailová adresa ověřena na: jhu.edu
"G. Steven Bova", "GS Bova", "George..."Tampere University School of Medicine and Health Technology","BioMediTech","Johns HopkinsE-mailová adresa ověřena na: telamon1.us
Tamara LotanProfessor and Deputy Director for Research, Department of Pathology, Johns Hopkins UniversityE-mailová adresa ověřena na: jhmi.edu
Yezi ZhuUniversity of Texas, AustinE-mailová adresa ověřena na: austin.utexas.edu
Johann de BonoInstitute of Cancer ResearchE-mailová adresa ověřena na: icr.ac.uk
Kenneth PientaProfessor of Urology, Oncology, Pharmacology and Molecular Sciences, Johns Hopkins UniversityE-mailová adresa ověřena na: jhmi.edu
William G. NelsonProfessor of Oncology, Johns Hopkins University School of MedicineE-mailová adresa ověřena na: jhmi.edu
Jianfeng XuNorthShore University HealthSystemE-mailová adresa ověřena na: NorthShore.org
Alan W. PartinJohns HopkinsE-mailová adresa ověřena na: jhmi.edu
Shan ZhaInstitute for Cancer Genetics, Columbia UniversityE-mailová adresa ověřena na: columbia.edu
Elizabeth A. PlatzProfessor, Department of Epidemiology, Johns Hopkins Bloomberg School of PublicE-mailová adresa ověřena na: jhu.edu
Shawn E. LupoldJohns Hopkins School of MedicineE-mailová adresa ověřena na: jhmi.edu
Meltem GürelPhD Researcher at University of CambridgeE-mailová adresa ověřena na: cam.ac.uk
Wasim H. ChowdhuryUT Health, San AntonioE-mailová adresa ověřena na: uthscsa.edu
Tabrez Mohammad, Ph.D.AbbVie, South San FranciscoE-mailová adresa ověřena na: abbvie.com

Sledovat

Jun Luo

Urology, Johns Hopkins University

E-mailová adresa ověřena na: jhmi.edu - Domovská stránka

prostate cancer


Název Seřadit podle citací Seřadit podle roku Seřadit podle názvu	Citace Citace	Rok
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, JC Roeser, ... New England Journal of Medicine 371 (11), 1028-1038, 2014	2980	2014
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer R Hu, TA Dunn, S Wei, S Isharwal, RW Veltri, E Humphreys, M Han, ... Cancer research 69 (1), 16-22, 2009	1336	2009
α-Methylacyl-CoA racemase: a new molecular marker for prostate cancer J Luo, S Zha, WR Gage, TA Dunn, JL Hicks, CJ Bennett, CM Ewing, ... Cancer research 62 (8), 2220-2226, 2002	829	2002
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer W Liu, S Laitinen, S Khan, M Vihinen, J Kowalski, G Yu, L Chen, ... Nature medicine 15 (5), 559-565, 2009	765	2009
Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, M Nakazawa, R Nadal, ... JAMA oncology 1 (5), 582-591, 2015	708	2015
Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling J Luo, DJ Duggan, Y Chen, J Sauvageot, CM Ewing, ML Bittner, JM Trent, ... Cancer research 61 (12), 4683-4688, 2001	671	2001
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer R Hu, C Lu, EA Mostaghel, S Yegnasubramanian, M Gurel, C Tannahill, ... Cancer research 72 (14), 3457-3462, 2012	666	2012
Breaking the scaling relationship via thermally stable Pt/Cu single atom alloys for catalytic dehydrogenation G Sun, ZJ Zhao, R Mu, S Zha, L Li, S Chen, K Zang, J Luo, Z Li, SC Purdy, ... Nature Communications 9 (1), 4454, 2018	621	2018
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis B Gurel, T Iwata, C M Koh, RB Jenkins, F Lan, C Van Dang, JL Hicks, ... Modern pathology 21 (9), 1156-1167, 2008	524	2008
miR-21: an androgen receptor–regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth J Ribas, X Ni, M Haffner, EA Wentzel, AH Salmasi, WH Chowdhury, ... Cancer research 69 (18), 7165-7169, 2009	506	2009
Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with … ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, Y Zhu, JL Silberstein, ... Journal of clinical oncology 35 (19), 2149-2156, 2017	475	2017
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer A Sharp, I Coleman, W Yuan, C Sprenger, D Dolling, DN Rodrigues, ... The Journal of clinical investigation 129 (1), 192-208, 2019	386	2019
Armet, a UPR-upregulated protein, inhibits cell proliferation and ER stress-induced cell death A Apostolou, Y Shen, Y Liang, J Luo, S Fang Experimental cell research 314 (13), 2454-2467, 2008	349	2008
Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study AJ Armstrong, S Halabi, J Luo, DM Nanus, P Giannakakou, ... Journal of Clinical Oncology 37 (13), 1120-1129, 2019	339	2019
The mutational landscape of prostate cancer CE Barbieri, CH Bangma, A Bjartell, JWF Catto, Z Culig, H Grönberg, ... European urology 64 (4), 567-576, 2013	303	2013
Human prostate cancer precursors and pathobiology AM De Marzo, AK Meeker, S Zha, J Luo, M Nakayama, EA Platz, ... Urology 62 (5), 55-62, 2003	296	2003
DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases MJ Aryee, W Liu, JC Engelmann, P Nuhn, M Gurel, MC Haffner, D Esopi, ... Science translational medicine 5 (169), 169ra10-169ra10, 2013	288	2013
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study MT Schweizer, ES Antonarakis, H Wang, AS Ajiboye, A Spitz, H Cao, ... Science translational medicine 7 (269), 269ra2-269ra2, 2015	279	2015
A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities R Hu, WB Isaacs, J Luo The Prostate 71 (15), 1656-1667, 2011	250	2011
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects R Ferraldeschi, J Welti, J Luo, G Attard, JS De Bono Oncogene 34 (14), 1745-1757, 2015	218	2015

Systém momentálně nemůže danou operaci provést. Zkuste to znovu později.

Články 1–20

Citace za rok

Duplicitní citace

Sloučené citace

Přidat spoluautorySpoluautoři

Sledovat

Citace

Spoluautoři